Francesco M Fusco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3014607/publications.pdf

Version: 2024-02-01

64 papers

1,555 citations

361045 20 h-index 329751 37 g-index

68 all docs 68 docs citations

68 times ranked 2795 citing authors

#	Article	IF	CITATIONS
1	Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in NaÃve HIV patients. Brain Research Bulletin, 2022, 181, 129-143.	1.4	1
2	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemicâ€"Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 2022, 11, 609.	1.3	7
3	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	1.8	87
4	Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. Scientific Reports, 2021, 11, 2941.	1.6	102
5	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Frontiers in Medicine, 2021, 8, 639970.	1.2	20
6	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. Journal of Antimicrobial Chemotherapy, 2021, 76, 2380-2393.	1.3	13
7	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10.	1.1	2
8	The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism. International Journal of Molecular Sciences, 2021, 22, 9548.	1.8	56
9	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. Open Forum Infectious Diseases, 2020, 7, ofaa456.	0.4	16
10	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	1.8	98
11	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	1.1	137
12	Switching from boosted Pls to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. Journal of Antimicrobial Chemotherapy, 2020, 75, 3334-3343.	1.3	5
13	Persons living with HIV may be reluctant to access to COVID-19 testing services: data from  D. Cotugno' Hospital, Naples, Southern Italy. Aids, 2020, 34, 2151-2152.	1.0	6
14	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. European Journal of Internal Medicine, 2020, 82, 38-47.	1.0	88
15	COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study. Journal of Hospital Infection, 2020, 105, 596-600.	1.4	76
16	Microelimination of HCV in residual populations of coinfected HIV/HCV: real-life data from an hospital setting in Southern Italy. Digestive and Liver Disease, 2020, 52, e25.	0.4	0
17	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular Pharmacology, 2020, 135, 106805.	1.0	39
18	Differences among confirmed and not-confirmed COVID-19 patients at "D.Cotugno" hospital, Naples (Italy): what we learned from first suspected cases?. Infezioni in Medicina, 2020, 28, 84-88.	0.7	3

#	Article	IF	CITATIONS
19	Use of lung ultrasound in COVID-19: comparison with ultra-high-resolution computed tomography among 29 patients at "D. Cotugno" hospital, Naples, Italy. Infezioni in Medicina, 2020, 28, 346-350.	0.7	8
20	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEATO22 Study. Clinical Infectious Diseases, 2019, 68, 597-606.	2.9	34
21	Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005–2015 systematic review. BMC Infectious Diseases, 2019, 19, 653.	1.3	64
22	Transportation capacity for patients with highly infectious diseases in Europe: a survey in 16 nations. Clinical Microbiology and Infection, 2019, 21, e1-e5.	2.8	11
23	Occupational transmission of an Orthopoxvirus infection during an outbreak in a colony of <i>Macaca tonkeana</i> in Lazio Region, Italy, 2015. Zoonoses and Public Health, 2018, 65, 578-583.	0.9	7
24	Reasons for switching ART: Comparison of data collected in 2012–2013 and 2014–2015 in Florence, Italy. International Journal of STD and AIDS, 2018, 29, 392-395.	0.5	1
25	Highly infectious diseases in the Mediterranean Sea area: Inventory of isolation capabilities and recommendations for appropriate isolation. New Microbes and New Infections, 2018, 26, S65-S73.	0.8	4
26	Overuse of antimicrobials and over-hospitalization in an adult measles cluster in the Florence area during the ongoing Italian outbreak. Infection, 2018, 46, 891-892.	2.3	2
27	Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016. Vaccine, 2018, 36, 5962-5966.	1.7	8
28	Clinical presentation and outcome of twenty cases of Invasive Meningococcal Disease due to Serogroup C – Clonal complex 11 in the Florence province, Italy, 2015–2016. Journal of Infection, 2017, 74, 210-213.	1.7	2
29	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14. Journal of Antimicrobial Chemotherapy, 2017, 72, 2837-2845.	1.3	15
30	The contribution of the European high containment laboratories during the 2014–2015 Ebola Virus Disease emergency. Clinical Microbiology and Infection, 2017, 23, 58-60.	2.8	3
31	Sampling Surfaces for Ebola Virus Persistence After Cleaning Procedures in High-Level Isolation Settings: The Experience With 2 Patients at the Lazzaro Spallanzani National Institute for Infectious Diseases. Infection Control and Hospital Epidemiology, 2016, 37, 723-725.	1.0	4
32	Non-randomised Ebola trialsâ€"lessons for optimal outbreak research. Lancet Infectious Diseases, The, 2016, 16, 407-408.	4.6	5
33	Enabling Rapid Response to the 2014–2016 Ebola Epidemic: The Experience and the Results of the National Institute for Infectious Diseases Lazzaro Spallanzani. Advances in Experimental Medicine and Biology, 2016, 972, 103-122.	0.8	2
34	Three cases of Zika virus imported in Italy: need for a clinical awareness and evidence-based knowledge. BMC Infectious Diseases, 2016, 16, 669.	1.3	7
35	A 2009 cross-sectional survey of procedures for post-mortem management of highly infectious disease patients in 48 isolation facilities in 16 countries: data from EuroNHID. Infection, 2016, 44, 57-64.	2.3	12
36	Adopting a Global Safety Standard for the Prevention of Ebola Needle-Stick Exposures. Infection Control and Hospital Epidemiology, 2015, 36, 745-746.	1.0	2

#	Article	IF	CITATIONS
37	Ebola: missed opportunities for Europe–Africa research. Lancet Infectious Diseases, The, 2015, 15, 1254-1255.	4.6	13
38	Considerations regarding safe transport and transfer for Ebola patients in western countries. Intensive Care Medicine, 2015, 41, 1175-1176.	3.9	4
39	The added value of long-lasting preparedness for the management of a patient with Ebola. European Journal of Internal Medicine, 2015, 26, 451-452.	1.0	7
40	Hospital preparedness for knowledge-based response to Ebola and other emerging infectious diseases: A continuous challenge. European Journal of Internal Medicine, 2015, 26, 454-455.	1.0	4
41	Isolation Facilities for Highly Infectious Diseases in Europe – A Cross-Sectional Analysis in 16 Countries. PLoS ONE, 2014, 9, e100401.	1.1	22
42	Letter to the editor: Management of patients with Ebola virus disease in Europe: high-level isolation units should have a key role. Eurosurveillance, 2014, 19, 20993.	3.9	6
43	Infection control in the emergency department. Cmaj, 2012, 184, 1065.3-1065.	0.9	0
44	Biosecurity Measures in 48 Isolation Facilities Managing Highly Infectious Diseases. Biosecurity and Bioterrorism, 2012, 10, 208-214.	1.2	6
45	Personal Protective Equipment Management and Policies: European Network for Highly Infectious Diseases Data from 48 Isolation Facilities in 16 European Countries. Infection Control and Hospital Epidemiology, 2012, 33, 1008-1016.	1.0	18
46	Diagnostic issues and capabilities in 48 isolation facilities in 16 European countries: data from EuroNHID surveys. BMC Research Notes, 2012, 5, 527.	0.6	5
47	Infection control practices in facilities for highly infectious diseases across Europe. Journal of Hospital Infection, 2012, 81, 184-191.	1.4	14
48	Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries. BMC Infectious Diseases, 2012, 12, 27.	1.3	32
49	Influenza A (H1N1) in Rome, Italy in family: three case reports. Cases Journal, 2009, 2, 9123.	0.4	4
50	Isolation rooms for highly infectious diseases: an inventory of capabilities in European countries. Journal of Hospital Infection, 2009, 73, 15-23.	1.4	26
51	Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Medicine, 2009, 7, 15.	2.3	76
52	EuroNHID checklists for the assessment of high-level isolation units and referral centres for highly infectious diseases: results from the pilot phase of a European survey. Clinical Microbiology and Infection, 2009, 15, 711-719.	2.8	21
53	Facing the threat of highly infectious diseases in Europe: the need for a networking approach. Clinical Microbiology and Infection, 2009, 15, 706-710.	2.8	4
54	Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases. Lancet Infectious Diseases, The, 2009, 9, 45-56.	4.6	97

#	ARTICLE	IF	CITATION
55	Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease. Lancet Infectious Diseases, The, 2009, 9, 301-311.	4.6	69
56	Case definition for Ebola and Marburg haemorrhagic fevers: a complex challenge for epidemiologists and clinicians. New Microbiologica, 2009, 32, 359-67.	0.1	19
57	Noninvasive positive-pressure ventilation. Cmaj, 2008, 178, 597-598.	0.9	0
58	Meningococcal disease in an ambulance worker. Eurosurveillance, 2008, 13, 9-10.	3.9	3
59	Risk management of febrile respiratory illness in emergency departments. New Microbiologica, 2008, 31, 165-73.	0.1	7
60	Biocontainment Patient Care Units. Biosecurity and Bioterrorism, 2007, 5, 86-86.	1.2	0
61	A curriculum for training healthcare workers in the management of highly infectious diseases. Eurosurveillance, 2007, 12, 5-6.	3.9	22
62	Fever of unknown origin: a systematic review of the literature for 1995???2004. Nuclear Medicine Communications, 2006, 27, 205-211.	0.5	92
63	Brucellosis with erythema nodosum-like manifestations diagnosed by isolated positivity of the ELISA test for anti-Brucella IgM. Infezioni in Medicina, 2005, 13, 255-8.	0.7	2
64	Outbreak of cutaneous larva migrans in Naples, southern Italy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 491-492.	0.7	30